Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.

Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann

Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann.

Kidney Int ; 98(6): 1621, 2020 Dec.

Article en En | MEDLINE | ID: mdl-33276869

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Kidney Int Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google